Harrow reported record third-quarter revenue of better than $99 million. It guided revenue of between $350 and $365 million this year and fourth-quarter adjusted EBITDA of better than $33 million.
HROW · Harrow, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Close
- $32.13
- Open
- $31.99
- Day range
- $31.39–32.47
- 52-week closing range
- $26.04–54.80
- Average volume, 30 days
- 708K
- Short interest
- 7.1M · 18.9% of shares · 14.1 days
- Short volume, last session
- 59%
- Last earnings
- Nov 10, 2026
- Latest filing
- 10-Q · Nov 9
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
Harrow furnished a November 2026 investor presentation for the Jefferies Global Healthcare Conference, reporting Q3 2026 revenue of $99.3M and full-year 2026 revenue guidance of $350M–$365M.
Harrow reported record third-quarter revenue of $99.3 million, reaffirmed full-year revenue guidance of $350 million to $365 million, and reduced its adjusted EBITDA outlook to more than $40 million.
Harrow’s total revenues, net rose to $99,297,000 for the three months ended September 30, 2026. It completed the $30,000,000 TYRVAYA acquisition on October 1, 2026 and expects revenue in excess of $30,000,000 in 2027.
Harrow reported record third-quarter revenue of $99.3 million and GAAP net income of $9.8 million, but lowered full-year 2026 Adjusted EBITDA guidance to more than $40 million from $80 million to $100 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 10, 2026TL;DR. Record quarterly revenue, strong VEVYE and TRIESENCE performance, reaffirmed revenue guidance, and an accelerated G-MELT NDA submission are the key positives. The key negatives are the substantial adjusted EBITDA guidance reduction, first-half revenue miss, lower-than-expected gross margins, QUELL's missed primary endpoint, BYOOVIZ's launch revenue miss, and negative nine-month operating cash flow.
- + Third-quarter revenue reached a record $99.3 million, up 41% sequentially and 39% year over year.
- + Branded revenue rose 62% year over year to $83.5 million and represented approximately 84% of total revenue.
- + VEVYE delivered record revenue and prescription growth and secured a major coverage win.
- + TRIESENCE delivered record quarterly revenue and unit demand.
- + Full-year revenue guidance was reaffirmed at $350 million to $365 million.
- + G-MELT remains on track for an NDA submission before the end of 2026, meaningfully ahead of schedule.
- − Full-year adjusted EBITDA guidance was reduced from $80 million-$100 million to a floor of more than $40 million.
- − First-half revenue finished approximately $28 million below the midpoint of initial guidance.
- − Gross margins were lower than expected because of compounding-revenue margins and product mix.
- − The QUELL study failed to establish IHEEZO's non-inferiority on its primary endpoint.
- − BYOOVIZ generated a revenue miss relative to launch expectations.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| ADJ. EBITDA non-GAAP | $21.2M | Q3 2026 | — |
| Adjusted EBITDA non-GAAP | $7,327,000 | Nine Months Ended September 30, 2026 | — |
|
|
|||
| Branded revenue | $83.5M | Third Quarter 2026 | +61.9% |
|
|
|||
| Compounding revenue, net | $15,835,000 | Three Months Ended September 30, 2026 | -21.0% |
|
|
|||
| GAAP gross margin | 75% | the third quarter of 2026 | — |
| IHEEZO | $25,297,000 | Three Months Ended September 30, 2026 | +15.5% |
|
|
|||
| IHEEZO revenue | $25.3M | Third Quarter 2026 | +15.5% |
|
|
|||
| Other branded products | $7,595,000 | Three Months Ended September 30, 2026 | +140.4% |
|
|
|||
| Record quarterly unit demand | 20,022 | Third Quarter 2026 | — |
| Segment contribution (Branded) | $20,911,000 | the three months ended September 30, 2026 filing | — |
| Segment contribution (Compounding) | $712,000 | the three months ended September 30, 2026 filing | — |
| Sequential Unit Growth | 37% | Q3 2026 vs. Q2 2026 | — |
| TRIESENCE revenue | $10.7M | Third Quarter 2026 | — |
|
|
|||
| Unit demand | 62,210 | Third Quarter 2026 | — |
| VEVYE revenue | $39.7M | Third Quarter 2026 | — |
|
|
|||
| Branded TRx market share | 14.6% | Q2 2026 | — |
| Compounding gross margin | 52.8% | Three Months Ended June 30, 2026 filing | — |
| Reorder rate | 85.5% | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HROW
this stock
Harrow, Inc.
|
$1.21B | -34.4% | +36.4% | — | 18.9% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.40B | +37.3% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$50.89B | +5.3% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$44.97B | +23.5% | +4.3% | 87.6 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 18, 2026
- This year
- 23
Harrow reported record third-quarter revenue of better than $99 million. It guided revenue of between $350 and $365 million this year and fourth-quarter adjusted EBITDA of better than $33 million.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HROW | +13.5% | +14.1% | -5.8% | +13.8% | -34.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +19.0% | +20.4% | -0.2% | +19.0% | -39.4% |